BioCentury | Mar 13, 2020
Finance

Cratering market spoils Imara’s NASDAQ debut

Imara managed to make its public debut Thursday after raising $75.2 million in an IPO; however, the hemoglobinopathy company’s shares were immediately swept up in Thursday’s market turmoil. Imara Inc. (NASDAQ:IMRA) slipped $1 to $15...
BioCentury | Feb 18, 2020
Finance

Feb. 18 Financial Quick Takes: Imara's IPO filing, Passage's terms, and fundings for OMass and Univercells

Imara listing would bring liquidity to NEA-led group Hematology company Imara Inc. filed to raise up to $86.3 million in an IPO on NASDAQ. The company's prospectus said New Enterprise Associates is its largest shareholder...
BioCentury | Sep 14, 2019
Financial News

Sept. 13 Financial Quick Takes: Satsuma prices IPO; plus Catalyst scuttles fund-raising and Imara plans a listing

Satsuma raises $82.5M in NASDAQ listing Migraine company Satsuma Pharmaceuticals Inc. (NASDAQ:STSA) gained $1.90 (13%) to $16.90 after raising $82.5 million in a bumped-up IPO. The company sold 5.5 million shares, upsized from the proposed...
BioCentury | Mar 18, 2019
Financial News

OrbiMed, Arix lead Imara's $63M B round

Imara will use its $63 million series B round to prepare lead compound IMR-687 for a Phase III program in adults with sickle cell disease, and to position the oral phosphodiesterase-9 (PDE-9) inhibitor for pediatric...
BioCentury | Oct 20, 2017
Financial News

Orphan drug accelerator Cydan raises $34M

Cydan Development Inc. (Cambridge, Mass.), which operates an accelerator that spins out rare genetic disease companies, raised $34 million on Oct. 17 in a round led by existing investor New Enterprise Associates (NEA). New investor...
BioCentury | Oct 20, 2017
Finance

Fast inflections

Longitude Capital joined Cydan Development Inc. ’s syndicate with the expectation that spinouts from the rare disease accelerator can deliver returns within three to five years. The company sources rare disease assets from academia, not-for-profits...
BioCentury | Oct 17, 2017
Financial News

Orphan drug accelerator Cydan raises $34M

Cydan Development Inc. (Cambridge, Mass.), which operates an accelerator that spins out rare genetic disease companies, raised $34 million in a round led by existing investor New Enterprise Associates (NEA). New investor Longitude Capital and...
BioCentury | Jun 9, 2017
Regulation

New SOC in sickle cell?

If FDA follows ODAC’s recommendation to approve Endari L-glutamine from Emmaus Life Sciences Inc. , the candidate is likely to become the backbone of sickle cell therapy. On May 24, FDA’s Oncologic Drugs Advisory Committee voted...
BioCentury | May 26, 2017
Clinical News

FDA grants IMR-687 rare pediatric disease designation

Imara Inc. (Cambridge, Mass.) said FDA granted rare pediatric disease designation to IMR-687 to treat sickle cell disease (SCD). Imara said it is the first SCD candidate to receive the designation from the agency. The...
BioCentury | Dec 6, 2016
Clinical News

IMR-687: Ph I started

Imara began a double-blind, placebo-controlled, U.S. Phase I trial to evaluate oral IMR-687 in about 42 healthy volunteers. Imara has exclusive, worldwide rights to IMR-687 from H. Lundbeck (see BioCentury, April 18 ). Imara Inc....
Items per page:
1 - 10 of 232
BioCentury | Mar 13, 2020
Finance

Cratering market spoils Imara’s NASDAQ debut

Imara managed to make its public debut Thursday after raising $75.2 million in an IPO; however, the hemoglobinopathy company’s shares were immediately swept up in Thursday’s market turmoil. Imara Inc. (NASDAQ:IMRA) slipped $1 to $15...
BioCentury | Feb 18, 2020
Finance

Feb. 18 Financial Quick Takes: Imara's IPO filing, Passage's terms, and fundings for OMass and Univercells

Imara listing would bring liquidity to NEA-led group Hematology company Imara Inc. filed to raise up to $86.3 million in an IPO on NASDAQ. The company's prospectus said New Enterprise Associates is its largest shareholder...
BioCentury | Sep 14, 2019
Financial News

Sept. 13 Financial Quick Takes: Satsuma prices IPO; plus Catalyst scuttles fund-raising and Imara plans a listing

Satsuma raises $82.5M in NASDAQ listing Migraine company Satsuma Pharmaceuticals Inc. (NASDAQ:STSA) gained $1.90 (13%) to $16.90 after raising $82.5 million in a bumped-up IPO. The company sold 5.5 million shares, upsized from the proposed...
BioCentury | Mar 18, 2019
Financial News

OrbiMed, Arix lead Imara's $63M B round

Imara will use its $63 million series B round to prepare lead compound IMR-687 for a Phase III program in adults with sickle cell disease, and to position the oral phosphodiesterase-9 (PDE-9) inhibitor for pediatric...
BioCentury | Oct 20, 2017
Financial News

Orphan drug accelerator Cydan raises $34M

Cydan Development Inc. (Cambridge, Mass.), which operates an accelerator that spins out rare genetic disease companies, raised $34 million on Oct. 17 in a round led by existing investor New Enterprise Associates (NEA). New investor...
BioCentury | Oct 20, 2017
Finance

Fast inflections

Longitude Capital joined Cydan Development Inc. ’s syndicate with the expectation that spinouts from the rare disease accelerator can deliver returns within three to five years. The company sources rare disease assets from academia, not-for-profits...
BioCentury | Oct 17, 2017
Financial News

Orphan drug accelerator Cydan raises $34M

Cydan Development Inc. (Cambridge, Mass.), which operates an accelerator that spins out rare genetic disease companies, raised $34 million in a round led by existing investor New Enterprise Associates (NEA). New investor Longitude Capital and...
BioCentury | Jun 9, 2017
Regulation

New SOC in sickle cell?

If FDA follows ODAC’s recommendation to approve Endari L-glutamine from Emmaus Life Sciences Inc. , the candidate is likely to become the backbone of sickle cell therapy. On May 24, FDA’s Oncologic Drugs Advisory Committee voted...
BioCentury | May 26, 2017
Clinical News

FDA grants IMR-687 rare pediatric disease designation

Imara Inc. (Cambridge, Mass.) said FDA granted rare pediatric disease designation to IMR-687 to treat sickle cell disease (SCD). Imara said it is the first SCD candidate to receive the designation from the agency. The...
BioCentury | Dec 6, 2016
Clinical News

IMR-687: Ph I started

Imara began a double-blind, placebo-controlled, U.S. Phase I trial to evaluate oral IMR-687 in about 42 healthy volunteers. Imara has exclusive, worldwide rights to IMR-687 from H. Lundbeck (see BioCentury, April 18 ). Imara Inc....
Items per page:
1 - 10 of 232